AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37137388 — intervention group
Group type: COMPARATOR
Intervention: TOFscan
Number of subjects: 100
Study 37137444 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gene Decipher genomic classifier (GC)
Number of subjects: 215
Study 37137444 — intervention group
Group type: COMPARATOR
Intervention: 22-gene Decipher genomic classifier (GC) low-risk patients
Number of subjects: 215
Study 37137444 — intervention group
Group type: COMPARATOR
Intervention: 22-gene Decipher genomic classifier (GC) lower scores
Number of subjects: 215
Study 37137527 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide
Number of subjects: 1278
Study 37137527 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1278
Study 37137553 — intervention group
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T therapy
Number of subjects: 1
Study 37137560 — intervention group
Group type: COMPARATOR
Intervention: Nurse practitioner roles implemented in three departments of a Belgian university hospital.
Number of subjects: 0
Study 37137586 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 65
Study 37137588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) (Lp[a])
Number of subjects: 1098
Study 37137588 — intervention group
Group type: EXPERIMENTAL
Intervention: OxPL-apoB
Number of subjects: 1098
Study 37137588 — intervention group
Group type: EXPERIMENTAL
Intervention: OxPL-apo(a)
Number of subjects: 1098
Study 37137590 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary-related hospitalizations among women
Number of subjects: 2979
Study 37137590 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncardiac hospitalizations among women
Number of subjects: 2979
Study 37137617 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate vitamin B
Number of subjects: 977
Study 37137617 — intervention group
Group type: COMPARATOR
Intervention: RBC folate deficiency (<305 nmol/L) and insufficiency (<748 nmol/L)
Number of subjects: 977
Study 37137660 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0
Study 37137672 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 248
Study 37137672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 37137673 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps-focused exercise (QE)
Number of subjects: 200
Study 37137673 — intervention group
Group type: COMPARATOR
Intervention: Hip-focused exercise (HE)
Number of subjects: 200
Study 37137675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trientine for 52 weeks
Number of subjects: 0
Study 37137675 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 52 weeks
Number of subjects: 0
Study 37137684 — intervention group
Group type: EXPERIMENTAL
Intervention: PPT diet
Number of subjects: 200
Study 37137684 — intervention group
Group type: COMPARATOR
Intervention: MED diet
Number of subjects: 200
Study 37138195 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly myopic eyes (AL ≥ 26 mm)
Number of subjects: 673
Study 37138195 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly myopic eyes (AL ≥ 28 mm)
Number of subjects: 673
Study 37138195 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 673
Study 37138195 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial length (AL)
Number of subjects: 673
Study 37138195 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (AL < 26 mm)
Number of subjects: 673
Study 37138202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-symptom threshold aerobic exercise (SSTAE) for 12 weeks in addition to ordinary rehabilitation
Number of subjects: 0
Study 37138202 — intervention group
Group type: COMPARATOR
Intervention: Ordinary rehabilitation
Number of subjects: 0
Study 37138202 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTAE
Number of subjects: 0
Study 37138228 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic organ communication in STEMI (SYSTEMI) study intervention
Number of subjects: 150
Study 37138243 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LS)
Number of subjects: 645
Study 37138243 — intervention group
Group type: COMPARATOR
Intervention: Open operation (OP)
Number of subjects: 645
Study 37138268 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative (QIC) intervention including learning sessions, action periods, and workshops informed by joint learning, co-design, and evidence-based practices.
Number of subjects: 0
Study 37138268 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative (QIC) intervention
Number of subjects: 0
Study 37138460 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine trial participation
Number of subjects: 349
Study 37138473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg intravenous every 2 weeks)
Number of subjects: 20
Study 37138473 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 37138742 — intervention group
Group type: EXPERIMENTAL
Intervention: New Echinacea formulation
Number of subjects: 246
Study 37138742 — intervention group
Group type: COMPARATOR
Intervention: Conventional Echinacea formulation
Number of subjects: 246
Study 37138751 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program
Number of subjects: 340
Study 37138751 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative care programs
Number of subjects: 340
Study 37138800 — intervention group
Group type: EXPERIMENTAL
Intervention: Doraya catheter
Number of subjects: 9
Study 37139076 — intervention group
Group type: EXPERIMENTAL
Intervention: Verticalization at 0°, -5°, 15°, 30°, 45°, and 70° using a standardized Sara Combilizer chair for 3-5 minutes each.
Number of subjects: 20
Study 37139182 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anxiety Disorder 7-Item (GAD-7) scale
Number of subjects: 200
Study 37139325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama-assisted TF-CBT
Number of subjects: 74
Study 37139325 — intervention group
Group type: COMPARATOR
Intervention: TF-CBT alone
Number of subjects: 74
Study 37139536 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine use
Number of subjects: 0
Study 37139536 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37139665 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant modified FOLFIRINOX (mFOLFIRINOX)
Number of subjects: 44
Study 37139665 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative plasma ctDNA analysis
Number of subjects: 44
Study 37139775 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (80 hours) and bimanual intensive therapy (20 hours)
Number of subjects: 21
Study 37139775 — intervention group
Group type: COMPARATOR
Intervention: Bimanual intensive therapy (80 hours) and modified constraint-induced movement therapy (20 hours)
Number of subjects: 21
Study 37139775 — intervention group
Group type: COMPARATOR
Intervention: Modified constraint-induced movement therapy (20 hours)
Number of subjects: 21
Study 37139775 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (80 hours)
Number of subjects: 21
Study 37139775 — intervention group
Group type: COMPARATOR
Intervention: Bimanual intensive therapy (20 hours)
Number of subjects: 21
Study 37139814 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAS (intracranial atherosclerotic stenosis)
Number of subjects: 3949
Study 37139814 — intervention group
Group type: COMPARATOR
Intervention: No ICAS
Number of subjects: 3949
Study 37139814 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAS
Number of subjects: 3949
Study 37139817 — intervention group
Group type: EXPERIMENTAL
Intervention: Transuterine Ultrasound-Guided Fetal Embolization
Number of subjects: 0
Study 37139815 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month educational intervention comprising a stroke video and riskometer app
Number of subjects: 100
Study 37139815 — intervention group
Group type: COMPARATOR
Intervention: 1-time counseling (Control)
Number of subjects: 100
Study 37139855 — intervention group
Group type: COMPARATOR
Intervention: Early peripheral sensory dysfunction (EPSD) identified through quantitative sensory testing (QST) in individuals without T2DM.
Number of subjects: 225
Study 37139855 — intervention group
Group type: COMPARATOR
Intervention: Metabolic syndrome in individuals with T2DM.
Number of subjects: 225
Study 37139855 — intervention group
Group type: COMPARATOR
Intervention: Skin advanced glycation end-products (AGEs) in individuals with T2DM.
Number of subjects: 225
Study 37139855 — intervention group
Group type: COMPARATOR
Intervention: T2DM and EPSD in longitudinal analysis.
Number of subjects: 225
Study 37139855 — intervention group
Group type: COMPARATOR
Intervention: EPSD in longitudinal analysis.
Number of subjects: 225
Study 37139855 — intervention group
Group type: COMPARATOR
Intervention: Sensory loss phenotype associated with EPSD.
Number of subjects: 225
Study 37139963 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab in combination with chemotherapy
Number of subjects: 0
Study 37139963 — intervention group
Group type: COMPARATOR
Intervention: Other first-choice drugs
Number of subjects: 0
Study 37140175 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 154
Study 37140175 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 154
Study 37140395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 1351
Study 37140395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 1351
Study 37140395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 1351
Study 37140460 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CBT and treatment as usual (TAU)
Number of subjects: 170
Study 37140460 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 170
Study 37140493 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine administration initiated by practitioners
Number of subjects: 40
Study 37140493 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day treatment engagement
Number of subjects: 40
Study 37140493 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at treatment visits
Number of subjects: 40
Study 37140493 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported overdose events
Number of subjects: 40
Study 37140493 — intervention group
Group type: EXPERIMENTAL
Intervention: ED clinician readiness
Number of subjects: 40
Study 37140517 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10,000-diluted topical epinephrine
Number of subjects: 66
Study 37140517 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 66
Study 37140539 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (0.8 mg/kg weekly; maximum 50 mg)
Number of subjects: 127
Study 37140539 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (active treatment)
Number of subjects: 127
Study 37140558 — intervention group
Group type: EXPERIMENTAL
Intervention: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 15/15 μg of GI.1/GII.4c genotype VLPs
Number of subjects: 240
Study 37140558 — intervention group
Group type: EXPERIMENTAL
Intervention: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 15/50 μg of GI.1/GII.4c genotype VLPs
Number of subjects: 240
Study 37140558 — intervention group
Group type: EXPERIMENTAL
Intervention: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 50/50 μg of GI.1/GII.4c genotype VLPs
Number of subjects: 240
Study 37140558 — intervention group
Group type: EXPERIMENTAL
Intervention: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 50/150 μg of GI.1/GII.4c genotype VLPs
Number of subjects: 240
Study 37140602 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 836880 monotherapy (720 mg Q3W)
Number of subjects: 21
Study 37140602 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 836880 (720 mg Q3W) plus ezabenlimab (240 mg Q3W)
Number of subjects: 21
Study 37140705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (3 doses during induction phase)
Number of subjects: 268
Study 37140727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide (single dose)
Number of subjects: 37
Study 37140896 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal transplantation of neural progenitors derived from human embryonic stem cells
Number of subjects: 0
Study 37140904 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial decolonization (BD) using intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to RT and repeated for 5 days every 2 weeks through RT.
Number of subjects: 77
Study 37140904 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 77
Study 37141002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical red light/near-infrared-emitting collar (combined: 660 nm, 740 nm, 810 nm, and 870 nm)
Number of subjects: 30
Study 37141002 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 30
Study 37141002 — intervention group
Group type: COMPARATOR
Intervention: Both active and sham users
Number of subjects: 30
Study 37141005 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led Facebook groups
Number of subjects: 119
Study 37141005 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally-guided Facebook groups
Number of subjects: 119
Study 37141005 — intervention group
Group type: COMPARATOR
Intervention: Both group types
Number of subjects: 119
Study 37141032 — intervention group
Group type: EXPERIMENTAL
Intervention: 2GETHER intervention (five-session hybrid group- and couple-based intervention delivered via videoconference)
Number of subjects: 200
Study 37141032 — intervention group
Group type: COMPARATOR
Intervention: Control (single-session HIV testing and risk reduction counseling protocol)
Number of subjects: 200
Study 37141036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 100
Study 37141036 — intervention group
Group type: COMPARATOR
Intervention: General Health Education (GHE)
Number of subjects: 100
Study 37141073 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-GBD
Number of subjects: 139
Study 37141073 — intervention group
Group type: COMPARATOR
Intervention: PT-GBD
Number of subjects: 139
Study 37141104 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange (WE) with warm water
Number of subjects: 296
Study 37141104 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange (WE) with 25% saline
Number of subjects: 296
Study 37141104 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange (WE) with 50% saline
Number of subjects: 296
Study 37141104 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 296
Study 37141104 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% saline
Number of subjects: 296
Study 37141104 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% saline
Number of subjects: 296
Study 37141104 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 296
Study 37141104 — intervention group
Group type: EXPERIMENTAL
Intervention: Water infusion
Number of subjects: 296
Study 37141225 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-education intervention (8 sessions over 12 weeks)
Number of subjects: 45
Study 37141225 — intervention group
Group type: COMPARATOR
Intervention: Control group (dialysis education alone)
Number of subjects: 45
Study 37141237 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) delivered with a tissue reflectance sensor; 5 cycles of ischemia/reperfusion in the non-paralyzed upper limb.
Number of subjects: 51
Study 37141237 — intervention group
Group type: COMPARATOR
Intervention: Sham control with cuff pressure at 30 mmHg for 5 minutes.
Number of subjects: 51
Study 37141260 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based inspiratory muscle training (IMT) using 30% of maximal inspiratory pressure, increasing by 10% weekly, 30 repetitions, twice a day for 6 weeks.
Number of subjects: 10
Study 37141260 — intervention group
Group type: COMPARATOR
Intervention: SHAM (IMT without load)
Number of subjects: 10
Study 37141260 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based inspiratory muscle training (IMT)
Number of subjects: 10
Study 37141291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy with lymph nodes station 10-11-12-13-14 sampling
Number of subjects: 0
Study 37141294 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 mg/kg
Number of subjects: 0
Study 37141294 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 75 mg/m²
Number of subjects: 0
Study 37141538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic cancer screening using endoscopic ultrasound and/or magnetic resonance cholangiopancreatography
Number of subjects: 252
Study 37141544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus platinum-doublet chemotherapy
Number of subjects: 358
Study 37141544 — intervention group
Group type: COMPARATOR
Intervention: Platinum-doublet chemotherapy alone
Number of subjects: 358
Study 37141601 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia Educational Tool
Number of subjects: 0
Study 37141601 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37141764 — intervention group
Group type: EXPERIMENTAL
Intervention: GLYT1 inhibitor (PF-03463275) 40 or 60 mg twice daily with cognitive training (CT)
Number of subjects: 71
Study 37141764 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (CT) alone
Number of subjects: 71
Study 37141828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for ≤35 cycles
Number of subjects: 124
Study 37141828 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-course pembrolizumab after disease progression
Number of subjects: 124
Study 37141847 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily
Number of subjects: 61
Study 37142055 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve blockade (FNB) with 1% lidocaine with adrenaline
Number of subjects: 80
Study 37142055 — intervention group
Group type: COMPARATOR
Intervention: Placebo FNB with 0.9% saline
Number of subjects: 80
Study 37142075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic resection
Number of subjects: 0
Study 37142075 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided dilation and evacuation
Number of subjects: 0
Study 37142092 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facing electronic health record prompts and an EHR-integrated everyday shared decision-making tool
Number of subjects: 1090
Study 37142092 — intervention group
Group type: COMPARATOR
Intervention: Preintervention phase
Number of subjects: 1090
Study 37142177 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS intervention (web-based training for parenting strategies after child brain injury)
Number of subjects: 83
Study 37142177 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control (TAU)
Number of subjects: 83
Study 37142177 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS intervention
Number of subjects: 83
Study 37142273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 45049
Study 37142273 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 45049
Study 37142273 — intervention group
Group type: COMPARATOR
Intervention: Cytisine vs Varenicline
Number of subjects: 45049
Study 37142291 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) plus ipilimumab
Number of subjects: 0
Study 37142291 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 0
Study 37142308 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (15 mg)
Number of subjects: 15
Study 37142308 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 15
Study 37142308 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (15 mg and 25 mg) with psychotherapy
Number of subjects: 15
Study 37142317 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic needs assessment (HNA)
Number of subjects: 147
Study 37142317 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 147
Study 37142335 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lipid-based nutrient supplement initiated preconceptionally (arm 1, n=217)
Number of subjects: 667
Study 37142335 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lipid-based nutrient supplement initiated at 12 weeks gestation (arm 2, n=230)
Number of subjects: 667
Study 37142335 — intervention group
Group type: COMPARATOR
Intervention: No maternal nutrition supplementation (arm 3, n=220)
Number of subjects: 667
Study 37142335 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention arms combined
Number of subjects: 667
Study 37142372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib plus trastuzumab (cohort A and B)
Number of subjects: 117
Study 37142372 — intervention group
Group type: COMPARATOR
Intervention: Tucatinib monotherapy (cohort C)
Number of subjects: 117
Study 37142373 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPU-MB with intravenous albumin-bound paclitaxel infusion every 3 weeks for up to six cycles (dose levels 1 to 5: 40-215 mg/m²)
Number of subjects: 17
Study 37142371 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus abiraterone (n=501)
Number of subjects: 1919
Study 37142371 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus abiraterone and enzalutamide (n=462)
Number of subjects: 1919
Study 37142371 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (n=502 in abiraterone trial; n=454 in abiraterone and enzalutamide trial)
Number of subjects: 1919
Study 37142383 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced frequency pembrolizumab
Number of subjects: 0
Study 37142383 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (not explicitly mentioned)
Number of subjects: 0
Study 37142388 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygenation (91-95% SpO2)
Number of subjects: 20